| Recruiting | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) Triple Negative Breast Cancer (TNBC) | Phase 2 | 2024-03-04 |
| Withdrawn | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2023-01-01 |
| Withdrawn | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Pa Peripheral T Cell Lymphoma | Phase 2 | 2023-01-01 |
| Completed | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2021-10-13 |
| Completed | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer | Phase 1 | 2021-10-05 |
| Completed | Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection | Phase 2 | 2021-09-20 |
| Completed | A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects Healthy Volunteers | Phase 1 | 2020-12-29 |
| Completed | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (C Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | 2019-11-28 |
| Completed | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T Cell Lymphoma | Phase 1 / Phase 2 | 2019-03-12 |
| Completed | Compassionate Use Study of Tenalisib (RP6530) Hematological Malignancies | Phase 1 / Phase 2 | 2018-11-28 |
| Completed | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Ref Non Hodgkin Lymphoma | Phase 2 | 2018-11-25 |
| Terminated | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cH Classical Hodgkin Lymphoma | Phase 1 | 2018-07-18 |
| Terminated | Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas Lymphoma | Phase 1 | 2017-05-11 |
| Terminated | Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals Healthy Volunteers, Asthma | Phase 1 / Phase 2 | 2016-11-03 |
| Completed | To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers Healthy | Phase 1 | 2016-02-01 |
| Completed | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 | 2015-09-01 |
| Completed | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Lymphoma, B-Cell, T-Cell Lymphoma | Phase 1 | 2013-11-01 |